All In Biotech

Drug Trial Radar · NCT04122742

Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.

Last checked: Nov 19, 2026Latest source record: Jan 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

154

Planned (sponsor's estimate)

Start

Oct 8, 2019

Primary completion

Oct 2025

Study completion Oct 2025

Sponsor

Lead sponsor
University Hospital, BordeauxAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 10, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rubinstein-Taybi syndrome (RSTS) is a rare and severe congenital developmental disorder characterized by congenital anomalies and intellectual disability with a long term memory deficit. The main challenge is to improve the intellectual and memory efficiency of these patients. CREBBP and EP300 are the two genes known to cause RSTS. Both paralogs play a major role in chromatin remodeling and encode for transcriptional co-activators interacting with many proteins. The aim of this pilot study is to characterize the histone acetylation profiles in order to identify specific acetylation markers during normal and pathological neuronal differentiation of cortical and pyramidal neurons in RSTS.

Conditions

  • Rubinstein-Taybi Syndrome

Interventions

  • skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.Procedure

    Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.

  • Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsyOther

    induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons

  • Histone acetylation profiles of cells of SRT patients with CREBBP mutationsOther

    Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing

  • Functional involvement of identified epigenetic alterationsOther

    Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.

  • Culture of lymphoblastoid line from blood sampleBiological

    Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Identification of a specific acetylation profile of RSTSTime frame: Inclusion visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire de Bordeaux

    Talence, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.